Applications published 2 September 2009

Gel useful for the delivery of ophthalmic drugs
Sigma-Tau Industrie Farmaceutiche Riunite 2094236*

Lipid growth factor formulations
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung von Pharmaka 2094237*

Improvements in or relating to amphoteric liposomes
novosom 2094238*

Liposome preparation by single-pass process
MediGene; Ludwig-Maximilians-Universitaet Muenchen 2094239*

Stable powder formulation containing an anticholinergic agent
Boehringer Ingelheim International 2094240*

Oral formulations
Ariad Pharmaceuticals 2094241*

Matrix-embedded compsns having organic acids and fatty acids
Novus International 2094242*

Anionic latex as a carrier for bioactive ingredients and methods for making and using the same
Mallard Creek Polymers 2091243*

Spray-freeze-drying process for the preparation of pellets comprising percolation drying
MediGene; Ludwig-Maximilians-Universitaet Muenchen 2094244*

Stable powder formulation containing a novel anticholinergic agent
Boehringer Ingelheim International; Boehringer Ingelheim Pharma 2094245*

Sustained-release compsn and method for producing the same
Takeda Pharmaceutical 2094246*

Stable polypeptide formulations
Amgen 2094247*

Ibuprofen compsn
McNeil-PPC 2094248*

Transdermal therapeutic system for administering the active substance buprenorphine
LTS Lohmann Therapie-Systeme 2094249*

• Transdermal therapeutic system comprising ion pair micro-reservoirs
LTS Lohmann Therapie-Systeme 2094250*

• Powder formulation for inhalation
Jagotec 2094251*

• Nutritional supplement compsn for treatment of ocular diseases
Novartis 2094252*

• Acetaminophen compsns having minimised side effects including reduced hepatoxicity
Soderling, Eric 2094253*

• Treatment of cachexia
Myotec Therapeutics 2094254*

• Modulators of beta-2-adrenergic receptor for treating conditions characterised by disorganised vasculature
University of Leicester 2094255*

• Method for alleviating kerato-conjunctivitis sicca
Winston Laboratories 2094256*

• Methods for improving bioavailability of a renin inhibitor
Novartis 2094257*

• Pharmaceutical compsn using aliskiren and avosentan
Novartis 2094258*

• Renin inhibitors for the prevention and treatment of hypertension in obese patients
Novartis 2094259*

• Treatment of lung cancer
Ramot at Tel-Aviv University 2094260*

• Pharmaceutical compsn containing naphthoquinone-based compound for intestine delivery system
Mazence; KT & G Co 2094261*

• Pharmaceutical compsn containing phenanthrenequinone-based compound for intestine delivery system
Mazence; KT & G Co 2094262*

• 2-adamantyl-butyramide derivatives as selective 11 beta-HSD1 inhibitors
Merck Patent 2094263*

• Clotrimazol for treating staphylococcal infections
E-Therapeutics 2094264*

• Pyrroloy[1,2-A]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents
Neurotone 2094265*

• CRTH2 antagonists
Argenta Discovery 2094266*

• 4-(1-amino-ethyl)-cyclohexylamine derivatives
Actelion Pharmaceuticals 2094267*

• Drug combinations with substituted diaryl ureas for the treatment of cancer
Bayer HealthCare 2094268*

• Pyrrolidinanilines
SmithKline Beecham 2094269*

• Delivery system for resperidone
NV Organon 2094270*

• Drug combinations for treating airway diseases
Boehringer Ingelheim International; Boehringer Ingelheim Pharma 2094271*

• Nitrogen containing substituted heterocycles as platelet ADP receptor inhibitors
Portola Pharmaceuticals 2094272*

• EP2 and EP4 agonists as agents for the treatment of influenza A viral infection
Bayer Schering Pharma 2094273*

• T-140 peptide analogues having CXCR4 super-agonist activity for bone marrow recovery
Biokine Therapeutics 2094274*

• Methods and formulations for improved bioavailability of antiprogestins
Repros Therapeutic 2094275*

• Anti-viral compounds
Abbott Laboratories 2094276*

• A compsn for treatment of atopic dermatitis comprising glucosamine and derivatives thereof and a method for treatment of atopic dermatitis using them
Kim, Soo-youl 2094277*

• Use of lipid containing particles comprising Quillaja saponins for the treatment of cancer
Duecom, Groenberg 2094278*

• Methods and compsns for treating influenza
Functional Genetics 2094279*

• Pharmaceutical agent having long-lasting effect of treating arthritic disorders
Seikagaku 2094280*

• Use of lipid conjugates in the treatment of diseases or disorders of the eye
Yissum Research Development Company of the Hebrew University of Jerusalem 2094281*

• Anti-TSG101 antibodies and their uses for treatment of viral infections
Functional Genetics 2094282*

• Method for in situ solidification of blood-polymer compsns for regenerative medicine and cartilage repair solutions
Bio Syntech Canada 2094283*

• Generation of oncolytic adenoviruses and uses thereof
Bayer Schering Pharma 2094284*

• Special extract, and use thereof for the prevention of cyclic guanosine monophosphate (CGMP) decomposition
Finzelberg 2094285*

• Compsns and methods of inducing hair growth utilising Cotinus coggygria
Johnson & Johnson Consumer Companies 2094286*

• Compsns and methods of using same for treatment of a disease or disorder of the eye and/or the adnexa of the eye
Ocumedic 2094287*

• Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
The Brigham and Women's Hospital 2094288*

• Conjoint therapies for treating fibrotic diseases
Promedior 2094289*

• Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor
Drugrecure 2094290*

• Dimeric prolactin receptor ligands
Novo Nordisk 2094291*

• Nitric oxide-blocked cross-linked tetrameric haemoglobin
Ikor 2094292*

• Tissue targeted antigenic activation of the immune response to treat cancers
Gunn, Harold David 2094293*

• Novel immunogenic compsns for the prevention and treatment of meningococcal disease
Wyeth 2094294*

• Method for the diagnosis and/or monitoring of invasive aspergillosis
Universita" Degli Studi di Modena E Reggio Emilia 2094295*

• Multicomponent vaccine
Duke University 2094296*

• Immunogenic and therapeutic compsns for streptococcus pyogenes
Novartis 2094297*

• Multivalent pneumococcal polysaccharide-protein conjugate compsn
Wyeth 2094298*

• Recombinant modified vaccinia virus ankara (MVA)-based vaccine for the avian flu
Paul-Erlich-Institut Bundesamt fuer Sera und Impfstoffe 2094299*

• Medicinal formulation for the treatment of hepatitis C
Shah, Rajesh 2094300*

• Poxviridae treatment comprising TAP-1 and/or TAP-2 as a molecular adjuvant
University of British Columbia 2094301*

• Methods for the treatment of LADA and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
MacroGenics 2094302*

• Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof
Novelix Therapeutics 2094303*

• Multivalent pneumococcal polysaccharide-protein conjugate compsn
Wyeth 2094304*

• Method for treating pathological conditions and bleomycin associated pulmonary fibrosis
Centocor Ortho Biotech 2094305*

• Treatment of IL-1-beta related diseases
XOMA Technology 2094306*

• TES7 and antibodies that bind thereto
Macrogenics West 2094307*

• Stable parenteral formulation containing a RSV inhibitor of a benzodiazepine structure
Novartis 2094308*

• Alpha-lactalbumin compsn
Nya Hamlet Pharma 2094309*

• Marker genes for use in the identification of chondrocyte phenotypic stability and in the screening of factors influencing cartilage production
Tigenix 2094310*

• Improved linkers for anchoring targeting ligands
Kereos 2094311*